BEIJING LUZHU BIOTECHNOLOGY CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.55 HKD | -0.72% |
|
-1.61% | -7.86% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Beijing Luzhu Biotechnology Co Ltd is a China-based company principally engaged in drug discovery, research and development and commercialization. The Company is also engaged in out-licensing human vaccines and therapeutic biologics. Its products under clinical development include recombinant herpes zoster vaccine LZ901, and antibody injection products K3 and K193. Its LZ901 is mainly used to prevent herpes zoster caused by varicella zoster virus in adults aged 50 and above. The Company operates in the domestic market and overseas markets.
Sector
Pharmaceuticals
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
25.6
CNY
Average target price
27.73
CNY
Spread / Average Target
+8.30%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.86% | 718M | |
| -2.35% | 89.33B | |
| +3.29% | 41.19B | |
| -15.40% | 31.87B | |
| +53.49% | 24.52B | |
| -14.35% | 15.68B | |
| -39.65% | 12.23B | |
| -6.52% | 12.34B | |
| -13.41% | 12.21B | |
| +6.22% | 8.83B |
- Stock Market
- Equities
- 2480 Stock
- News Beijing Luzhu Biotechnology Co., Ltd.
- Luzhu Biotechnology Ties Up With Tianjin Ringpu to Develop Pet Vaccines, Drugs
